Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Biohaven Ltd. (BHVN)
NYSE:BHVN
Holding BHVN?
Track your performance easily
BHVN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$26.80 - $62.21
Previous Close$46.83
Volume645.97K
Average Volume (3M)994.49K
Market Cap
$4.68B
Enterprise Value$4.33B
Total Cash (Recent Filing)$378.82M
Total Debt (Recent Filing)$25.31M
Price to Earnings (P/E)―
Beta1.83
Next Earnings
Mar 20, 2025EPS Estimate
-$1.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.35
Shares Outstanding101,122,246
10 Day Avg. Volume801,430
30 Day Avg. Volume994,489
Standard Deviation0.37
R-Squared0.19
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)15.01
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-8.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-7.40
Forecast
1Y Price Target
$65.64Price Target Upside45.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Biohaven Ltd. News
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessTroriluzole significantly slowed disease progression by 50% compared to U.S. natural history external control, demonstrating a favorable safety and tolerability profile.
Drug DevelopmentTaldefgrobep alfa could have an advantage due to its subcutaneous administration and potentially higher potency compared to competitors.
Pipeline ProgressBiohaven's focus on advancing numerous neurological treatment options positions it well in the biopharmaceutical landscape.
Bears Say
Clinical Trial RisksTroriluzole has a checkered history as the drug previously failed in a Ph2/3 SCA study in 2017, failed in a Ph3 trial in generalized anxiety disorder (GAD), failed in a Ph2/3 study in obsessive compulsive disorder (OCD), and failed in a Phase 2/3 study in Alzheimer's disease.
Financial PerformanceMinimal credit is reflected at Biohaven’s current valuation for taldefgrobep alfa, awaiting derisking results in spinal muscular atrophy (SMA) before formally ascribing value to the program.
Regulatory ChallengesThere is uncertainty regarding the FDA's acceptance of the study design for troriluzole, which lacked a placebo group.
---
Ownership Overview
14.59% Insiders
20.87% Mutual Funds
31.78% Other Institutional Investors
19.32% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BHVN FAQ
What was Biohaven Ltd.’s price range in the past 12 months?
Biohaven Ltd. lowest stock price was $26.80 and its highest was $62.21 in the past 12 months.
What is Biohaven Ltd.’s market cap?
Currently, no data Available
When is Biohaven Ltd.’s upcoming earnings report date?
Biohaven Ltd.’s upcoming earnings report date is Mar 20, 2025 which is in 119 days.
How were Biohaven Ltd.’s earnings last quarter?
Biohaven Ltd. released its earnings results on Nov 12, 2024. The company reported -$1.7 earnings per share for the quarter, beating the consensus estimate of -$1.702 by $0.002.
Is Biohaven Ltd. overvalued?
According to Wall Street analysts Biohaven Ltd.’s price is currently Undervalued.
Does Biohaven Ltd. pay dividends?
Biohaven Ltd. does not currently pay dividends.
What is Biohaven Ltd.’s EPS estimate?
Biohaven Ltd.’s EPS estimate is -$1.61.
How many shares outstanding does Biohaven Ltd. have?
Biohaven Ltd. has 101,122,246 shares outstanding.
What happened to Biohaven Ltd.’s price movement after its last earnings report?
Biohaven Ltd. reported an EPS of -$1.7 in its last earnings report, beating expectations of -$1.702. Following the earnings report the stock price went down -2.621%.
Which hedge fund is a major shareholder of Biohaven Ltd.?
Among the largest hedge funds holding Biohaven Ltd.’s share is Farallon Capital Management, L.L.C.. It holds Biohaven Ltd.’s shares valued at 182M.
---
Biohaven Ltd. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$65.64 (45.25% Upside)
$65.64 (45.25% Upside)
Blogger Sentiment
Bullish
BHVN Sentiment 85%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 2.0%
Last 30 Days ▲ 4.7%
Last 30 Days ▲ 4.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
53.03%
12-Months-Change
Fundamentals
Return on Equity
-265.45%
Trailing 12-Months
Asset Growth
33.39%
Trailing 12-Months
Company Description
Biohaven Ltd.
Biohaven Ltd is a commercial-stage biopharmaceutical company with a portfolio of innovative therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven's Neuroinnovation portfolio includes FDA-approved Nurtec ODT (rimegepant) for the acute and preventive treatment of migraine (EMA-approved as Vydura (rimegepant) for the acute treatment of migraine with or without aura, and prophylaxis of episodic migraine.
---
BHVN Stock 12 Month Forecast
Average Price Target
$65.64
▲(45.25% Upside)
Technical Analysis
Best Analysts Covering BHVN
1 Year
1 Year Success Rate
6/7 ratings generated profit
1 Year Average Return
+41.29%
reiterated a buy rating 2 months ago
Copying Tessa Romero's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +41.29% per trade.
---